Malignant pleural mesothelioma (Homo sapiens)

From WikiPathways

Revision as of 14:48, 21 May 2021 by Ziska (Talk | contribs)
Jump to: navigation, search
14-3-314-3-3562155447375713447717374151154517177453417777751151, 737747553TAMsChronic inflammation, proliferation, angiogenesis,resistance to apoptosisGFsCo-factorMMCell growth,differentiationNeoangiogenesisWntDegradationAsbestos fibersCell cycle progression &ProliferationGrowth arrestUbiquination degradationHippoAsbestos fibersMDM2Cell survivalRTKsAP-1 dependent genes/Repair genesWnt signalDNA-repairOther chemokines/cytokinesDNA-damageInflammationmTORMAPK, JAK-STATIncreased protein synthesis+ Cell growthAutophagyChemokines/Cytokines etc.Chemokines, Cytokines,Pro-angiogenic factorsIntegrinsTranscriptionAutophagyCell invasionInflammatory cytokines,cellular stressesCell growthCadherinsApoptosisMAPKBAXCASPASE-1PRAS40FAKULK1fra-1Cyclin DMMP2MLKTSC2TSC1STATAMOTNF-KBBCL2AJUBADR5FIP200JNK1-3DKK1LRPTCFHMGB1ERK1/2RHEBFZDATG13PTENPI3KLATS1/2BTRCGRB2MSIN1PIP3PIP2P53CDK2c-junTEL2CDK7AXIN14-3-3MTORSHCMEK4/7MMP9GTPBECLIN1PRBTTI1MST1/2GSK3NLRP3CTNNBL1VEGFDVLRAPTORRASMEK5BCLXLROSMEK1/2PUMAc-fos4E-BPDEPTORJAKPIGFP21MAPK14PDGFAKTAPCTEADERK2EIF4ATMMEK3/6HIF1ASOSMNKSRCMKCDK4LEFP14ARFFOXO1SFRPMCL1S6KNF2/merlinIL-1BPAK/RACCUL1RNSRICTORS6GDPCyclinD1MSKERK5MLST8MEKKASKPDK1RAFRAGEP16INK4ASAV1BAKKIBRACyclinEBAP1RSKE2FMDM2RASMSKMNKMKTEL2TTI1MLST8DEPTORMTORYAPTAZMDM2CTNNBL1P21BAXTAZCTNNBL1CTNNBL1Cell transformationTFCo-TFE2FPRBHMGB1HMGB1PRAS40RAPTORTEL2TTI1MLST8DEPTORMTORHMGB1IL-1BPro IL-1BP21YAPTAZChemokines, Cytokines,Pro-angiogenic factorsCell survival7


Description

Malignant Pleural Mesothelioma is a rare cancer affecting the mesothelial cells of the lungs. 80% of the patients have been exposed to asbestos before being diagnosed, but only 5% of the people exposed to asbestos develop mesothelioma. Therefore, genetics are thought to play an important role in combination with asbestos' toxicological effects. Several pathways have been identified to contribute to the development of the disease.

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. Hylebos M, Van Camp G, van Meerbeeck JP, Op de Beeck K; ''The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.''; J Thorac Oncol, 2016 PubMed Europe PMC Scholia
  2. Illei PB, Ladanyi M, Rusch VW, Zakowski MF; ''The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.''; Cancer, 2003 PubMed Europe PMC Scholia
  3. Liu Z, Klominek J; ''Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors.''; Thorax, 2003 PubMed Europe PMC Scholia
  4. Liu XL, Zuo R, Ou WB; ''The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.''; J Cancer Res Clin Oncol, 2018 PubMed Europe PMC Scholia
  5. Ghareghomi S, Ahmadian S, Zarghami N, Kahroba H; ''Fundamental insights into the interaction between telomerase/TERT and intracellular signaling pathways.''; Biochimie, 2021 PubMed Europe PMC Scholia
  6. Urso L, Calabrese F, Favaretto A, Conte P, Pasello G; ''Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.''; Crit Rev Oncol Hematol, 2016 PubMed Europe PMC Scholia
  7. Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, Stockhammer P, Lötsch-Gojo D, Gojo J, Gabler L, Spiegl-Kreinecker S, Dome B, Steindl A, Klikovits T, Hoda MA, Jakopovic M, Samarzija M, Mohorcic K, Kern I, Kiesel B, Brcic L, Oberndorfer F, Müllauer L, Klepetko W, Schmidt WM, Kumar R, Hegedus B, Berger W; ''Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.''; Clin Cancer Res, 2020 PubMed Europe PMC Scholia
  8. Benedetti S, Nuvoli B, Catalani S, Galati R; ''Reactive oxygen species a double-edged sword for mesothelioma.''; Oncotarget, 2015 PubMed Europe PMC Scholia
  9. Coleman SJ, Bruce C, Chioni AM, Kocher HM, Grose RP; ''The ins and outs of fibroblast growth factor receptor signalling.''; Clin Sci (Lond), 2014 PubMed Europe PMC Scholia
  10. Yap TA, Aerts JG, Popat S, Fennell DA; ''Novel insights into mesothelioma biology and implications for therapy.''; Nat Rev Cancer, 2017 PubMed Europe PMC Scholia
  11. Cakiroglu E, Senturk S; ''Genomics and Functional Genomics of Malignant Pleural Mesothelioma.''; Int J Mol Sci, 2020 PubMed Europe PMC Scholia
  12. Klominek J, Sumitran Karuppan S, Hauzenberger D; ''Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins.''; Int J Cancer, 1997 PubMed Europe PMC Scholia
  13. Tallet A, Nault JC, Renier A, Hysi I, Galateau-Sallé F, Cazes A, Copin MC, Hofman P, Andujar P, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D; ''Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.''; Oncogene, 2014 PubMed Europe PMC Scholia
  14. Sekido Y; ''Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.''; Pathol Int, 2011 PubMed Europe PMC Scholia
  15. Edwards JG, McLaren J, Jones JL, Waller DA, O'Byrne KJ; ''Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura.''; Br J Cancer, 2003 PubMed Europe PMC Scholia
  16. Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R; ''New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.''; Am J Pathol, 2013 PubMed Europe PMC Scholia
  17. Yuan X, Larsson C, Xu D; ''Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.''; Oncogene, 2019 PubMed Europe PMC Scholia
  18. Yuan X, Dai M, Xu D; ''TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends.''; Cancer Lett, 2020 PubMed Europe PMC Scholia
  19. Sekido Y; ''Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.''; Cancers (Basel), 2018 PubMed Europe PMC Scholia
  20. Napoli F, Listì A, Zambelli V, Witel G, Bironzo P, Papotti M, Volante M, Scagliotti G, Righi L; ''Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.''; Cancers (Basel), 2021 PubMed Europe PMC Scholia
  21. Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI; ''Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.''; CA Cancer J Clin, 2019 PubMed Europe PMC Scholia
  22. Crispi S, Calogero RA, Santini M, Mellone P, Vincenzi B, Citro G, Vicidomini G, Fasano S, Meccariello R, Cobellis G, Menegozzo S, Pierantoni R, Facciolo F, Baldi A, Menegozzo M; ''Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target.''; PLoS One, 2009 PubMed Europe PMC Scholia
  23. Chu GJ, van Zandwijk N, Rasko JEJ; ''The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy.''; Front Oncol, 2019 PubMed Europe PMC Scholia
  24. Dratwa M, Wysoczańska B, Łacina P, Kubik T, Bogunia-Kubik K; ''TERT-Regulation and Roles in Cancer Formation.''; Front Immunol, 2020 PubMed Europe PMC Scholia
  25. Xue J, Patergnani S, Giorgi C, Suarez J, Goto K, Bononi A, Tanji M, Novelli F, Pastorino S, Xu R, Caroccia N, Dogan AU, Pass HI, Tognon M, Pinton P, Gaudino G, Mak TW, Carbone M, Yang H; ''Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy.''; Proc Natl Acad Sci U S A, 2020 PubMed Europe PMC Scholia
  26. Dobrokhotov O, Samsonov M, Sokabe M, Hirata H; ''Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms.''; Clin Transl Med, 2018 PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
119680view18:06, 28 July 2021EgonwFixed a reference
119679view18:04, 28 July 2021EgonwReplaced secondary ChEBI identifiers with primary ones.
119668view12:40, 28 July 2021Marvin M2Added JNKs
119667view12:22, 28 July 2021Marvin M2Cleaning hippo part
119666view12:11, 28 July 2021Marvin M2Improved hippo pathway part
119659view10:58, 28 July 2021Marvin M2Added content in microenvironment
119654view09:58, 28 July 2021Marvin M2Made space and added microenvironment parts
119642view00:10, 28 July 2021ZiskaExtended Hippo-Merlin signalling
119641view20:58, 27 July 2021Marvin M2Added secretions by mesothelioma
119640view20:12, 27 July 2021Marvin M2Added ECM content, and MMP regulations
119630view20:52, 23 July 2021Marvin M2Added ECM-linked hippo signaling, pathway nodes, and started miroenvironment interactions
119629view13:16, 23 July 2021ZiskaAdded regulation of TERT
119595view11:31, 21 July 2021Marvin M2improved annotations
119594view11:23, 21 July 2021Marvin M2Labels added
119586view08:54, 21 July 2021Marvin M2Red coloring for tumor suppressor genes
119580view15:41, 20 July 2021Marvin M2Minor graphical updates
119579view15:33, 20 July 2021Marvin M2Modified description
119578view15:25, 20 July 2021Marvin M2Added pathway nodes, histone modifications
119576view15:59, 19 July 2021Marvin M2Pathway nodes added
119575view15:46, 19 July 2021Marvin M2Added CDKN2A and transcripts
119568view11:59, 16 July 2021ZiskaChanged shapes and colors and turnt headings into letters
119094view08:20, 17 June 2021FinterlyRemoved PublicationXref and corresponding BiopaxRef with no information
118962view10:50, 5 June 2021EweitzOntology Term : 'altered autophagy pathway' added !
117773view13:57, 22 May 2021EweitzModified title
117638view14:48, 21 May 2021ZiskaChanged group identifiers
116765view10:02, 12 May 2021ZiskaAdded identifier for PIP3
116740view15:26, 11 May 2021Marvin M2Enlarged asbestos for clarity
116739view15:15, 11 May 2021Marvin M2Updated layout
116665view12:45, 9 May 2021ZiskaAdded headings, moved pathway
116388view14:42, 6 May 2021Marvin M2Modified description
116333view15:25, 30 April 2021Marvin M2Ontology Term : 'mesothelial cell of pleura' added !
116332view15:23, 30 April 2021Marvin M2Ontology Term : 'disease pathway' added !
116331view15:23, 30 April 2021Marvin M2Ontology Term : 'mesothelial cell' added !
116330view15:23, 30 April 2021Marvin M2Ontology Term : 'malignant pleural mesothelioma' added !
116329view15:22, 30 April 2021Marvin M2Corrected name errors and connected lines
116302view09:16, 29 April 2021ZiskaNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
14-3-3ProteinA0A0J9YWE8 (Uniprot-TrEMBL)
4E-BPGeneProductENSG00000187840 (Ensembl)
AJUBAGeneProductENSG00000129474 (Ensembl)
AKTGeneProductENSG00000142208 (Ensembl)
AMOTGeneProductENSG00000126016 (Ensembl)
APCGeneProductENSG00000134982 (Ensembl)
ASKGeneProductENSG00000115687 (Ensembl)
ATG13GeneProductENSG00000175224 (Ensembl)
ATMGeneProductENSG00000149311 (Ensembl)
AXINGeneProductENSG00000168646 (Ensembl)
BAKGeneProductENSG00000030110 (Ensembl)
BAP1GeneProductENSG00000163930 (Ensembl)
BAXGeneProductENSG00000087088 (Ensembl)
BCL2GeneProductENSG00000171791 (Ensembl)
BCLXLGeneProductENSG00000171791 (Ensembl)
BECLIN1GeneProductENSG00000126581 (Ensembl)
BTRCGeneProductENSG00000166167 (Ensembl)
CASPASE-1GeneProductENSG00000137752 (Ensembl)
CDK2GeneProductENSG00000123374 (Ensembl)
CDK4GeneProductENSG00000135446 (Ensembl)
CDK7GeneProductENSG00000134058 (Ensembl)
CTNNBL1GeneProductENSG00000132792 (Ensembl)
CUL1GeneProductENSG00000055130 (Ensembl)
Cyclin DGeneProductENSG00000110092 (Ensembl)
CyclinD1GeneProductENSG00000110092 (Ensembl)
CyclinEGeneProductENSG00000105173 (Ensembl)
DEPTORGeneProductENSG00000155792 (Ensembl)
DKK1GeneProductENSG00000107984 (Ensembl)
DR5GeneProductENSG00000196363 (Ensembl)
DVLGeneProductENSG00000107404 (Ensembl)
E2FGeneProductENSG00000101412 (Ensembl)
EIF4GeneProductENSG00000114867 (Ensembl)
ERK1/2GeneProductENSG00000102882 (Ensembl)
ERK2GeneProductENSG00000100030 (Ensembl)
ERK5GeneProductENSG00000166484 (Ensembl)
FAKGeneProductENSG00000169398 (Ensembl)
FIP200GeneProductENSG00000023287 (Ensembl)
FOXO1GeneProductENSG00000150907 (Ensembl)
FZDGeneProductENSG00000157240 (Ensembl)
GDPMetaboliteCHEBI:17552 (ChEBI)
GRB2GeneProductENSG00000177885 (Ensembl)
GSK3GeneProductENSG00000105723 (Ensembl)
GTPMetaboliteCHEBI:37565 (ChEBI)
HIF1AGeneProductENSG00000100644 (Ensembl)
HMGB1GeneProductENSG00000189403 (Ensembl)
IL-1BGeneProductENSG00000125538 (Ensembl)
JAKGeneProductENSG00000162434 (Ensembl)
JNK1-3GeneProductENSG00000107643 (Ensembl)
KIBRAGeneProductENSG00000113645 (Ensembl)
LATS1/2GeneProductENSG00000131023 (Ensembl)
LEFGeneProductENSG00000138795 (Ensembl)
LRPGeneProductENSG00000123384 (Ensembl)
MAPK14GeneProductENSG00000112062 (Ensembl)
MCL1GeneProductENSG00000143384 (Ensembl)
MDM2GeneProductENSG00000135679 (Ensembl)
MEK1/2GeneProductENSG00000169032 (Ensembl)
MEK3/6GeneProductENSG00000034152 (Ensembl)
MEK4/7GeneProductENSG00000065559 (Ensembl)
MEK5GeneProductENSG00000137764 (Ensembl)
MEKKGeneProductENSG00000095015 (Ensembl)
MKGeneProductENSG00000110492 (Ensembl)
MLKGeneProductENSG00000168404 (Ensembl)
MLST8GeneProductENSG00000167965 (Ensembl)
MMP2GeneProductENSG00000087245 (Ensembl)
MMP9GeneProductENSG00000100985 (Ensembl)
MNKGeneProductENSG00000079277 (Ensembl)
MSIN1GeneProductENSG00000119487 (Ensembl)
MSKGeneProductENSG00000100784 (Ensembl)
MST1/2GeneProductENSG00000173531 (Ensembl)
MTORGeneProductENSG00000198793 (Ensembl)
NF-KBGeneProductENSG00000109320 (Ensembl)
NF2/merlinGeneProductENSG00000186575 (Ensembl)
NLRP3GeneProductENSG00000162711 (Ensembl)
P14ARFGeneProductENSG00000147889 (Ensembl)
P16INK4AGeneProductENSG00000147889 (Ensembl)
P21GeneProductENSG00000124762 (Ensembl)
P53GeneProductENSG00000141510 (Ensembl)
PAK/RACGeneProductENSG00000149269 (Ensembl)
PDGFGeneProductENSG00000197461 (Ensembl)
PDK1GeneProductENSG00000152256 (Ensembl)
PI3KGeneProductENSG00000121879 (Ensembl)
PIGFGeneProductENSG00000151665 (Ensembl)
PIP2MetaboliteCHEBI:18348 (ChEBI)
PIP3MetaboliteCHEBI:16618 (ChEBI)
PRAS40GeneProductENSG00000204673 (Ensembl)
PRBGeneProductENSG00000251655 (Ensembl)
PTENGeneProductENSG00000171862 (Ensembl)
PUMAGeneProductENSG00000105327 (Ensembl)
Pro IL-1BGeneProductENSG00000125538 (Ensembl)
RAFGeneProductENSG00000132155 (Ensembl)
RAGEGeneProductENSG00000204305 (Ensembl)
RAPTORGeneProductENSG00000141564 (Ensembl)
RASGeneProductENSG00000174775 (Ensembl)
RHEBGeneProductENSG00000106615 (Ensembl)
RICTORGeneProductENSG00000164327 (Ensembl)
RNSMetaboliteQ225595 (Wikidata)
ROSMetaboliteCHEBI:70982 (ChEBI)
RSKGeneProductENSG00000160469 (Ensembl)
S6GeneProductENSG00000137154 (Ensembl)
S6KGeneProductENSG00000071242 (Ensembl)
SAV1GeneProductENSG00000151748 (Ensembl)
SFRPGeneProductENSG00000104332 (Ensembl)
SHCGeneProductENSG00000160691 (Ensembl)
SOSGeneProductENSG00000115904 (Ensembl)
SRCGeneProductENSG00000197122 (Ensembl)
STATGeneProductENSG00000115415 (Ensembl)
TAZGeneProductENSG00000102125 (Ensembl)
TCFGeneProductENSG00000081059 (Ensembl)
TEADGeneProductENSG00000187079 (Ensembl)
TEL2GeneProductENSG00000100726 (Ensembl)
TSC1GeneProductENSG00000165699 (Ensembl)
TSC2GeneProductENSG00000103197 (Ensembl)
TTI1GeneProductENSG00000101407 (Ensembl)
ULK1GeneProductENSG00000177169 (Ensembl)
VEGFGeneProductENSG00000112715 (Ensembl)
YAPGeneProductENSG00000137693 (Ensembl)
c-fosMetaboliteCHEBI:62519 (ChEBI)
c-junGeneProductENSG00000177606 (Ensembl)
fra-1 GeneProductENSG00000175592 (Ensembl)

Annotated Interactions

No annotated interactions

Personal tools